Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. - Wikidata - wikimedia - TriplyDB

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

http://www.wikidata.org/entity/Q37535232

about

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches NK Cells in HIV Disease Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Enhancing Cancer Immunotherapy Via Activation of Innate Immunity Immunotherapy in the treatment of non-small cell lung cancer The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor Manufacturing Natural Killer Cells as Medicinal Products Features of Memory-Like and PD-1(+) Human NK Cell Subsets Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies Nivolumab in melanoma: latest evidence and clinical potential Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer Mechanisms of action of therapeutic antibodies for cancer Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa Immune checkpoint inhibitors in clinical trials CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients NK cell-based immunotherapies in Pediatric Oncology.Present and Future of Allogeneic Natural Killer Cell Therapy Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women.Natural killer cell therapy in children with relapsed leukemia.Cancer immunotherapy: Strategies for personalization and combinatorial approaches.Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.The role of checkpoints in the treatment of GBM The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.Immune based therapy for melanoma Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology.Clinical utility of natural killer cells in cancer therapy and transplantation.A brief personal history of cancer immunotherapy at Stanford: if these walls could talk….

P2860

Q26738359-78DCD6C6-2755-469A-8D14-B14FFFCD1C65 Q26751011-01B3F975-8E62-4CC6-BF78-3F6CF5ED676B Q26752518-4C928409-8559-46DE-9146-C435F3493C9E Q26752833-7B328FD2-79C8-4769-8F80-4AEF40E91A5C Q26765459-49AF3E49-0CD5-4CBA-A5E2-25E63B375CD5 Q26765845-B024610D-937B-480C-9BDB-4A617FA9BD78 Q26769884-2903D16A-D5EA-4A5D-BC83-CA5CB5135537 Q26772347-6CD0ADDA-003F-4DEE-951C-1CBCF98ED3BA Q26774678-4642CB66-8F5A-45D6-96F2-D02A0BFD9C3A Q26796313-146F1F8E-A92B-4C3F-BBE7-362430266FA2 Q27000382-CA6EB5F3-3D54-474B-9448-74FC09563668 Q27022789-AA574D7E-7644-46E4-AB88-E01F4AC5C89E Q28067468-24360366-238C-427A-8B7C-5B28BCA65CEF Q28069992-C912C444-3F64-4574-BD28-7B1025275318 Q28073988-9F384CBD-2747-4376-B9A9-8F9D1F3226FA Q28079180-20990647-B99D-41C1-A5D2-B47068BBF3E6 Q28258598-A555BD1A-0D18-480A-A92A-7FC43B961934 Q28266580-34822730-C5D8-4F56-8CEB-F22F38BE572D Q28385366-C0C5A3BC-A565-4459-8892-918CD2A75305 Q28607344-92F14CE5-53CD-44E0-9BB0-7D9BDCD38A51 Q34309394-FE60E9CB-BAC3-47AF-8127-77FEE10B2881 Q34688644-51432B3B-6254-4890-A60F-20DE5693119A Q35157421-56FC8CF1-3779-447E-A732-C5BBD263C172 Q35600975-3CD83C70-7A79-4615-B480-9CE6889E2C8A Q35677351-46149EB5-E12D-42E5-9D16-B1A5D3F1C8F2 Q35904239-AF33FE23-BB4F-471F-BA9D-E1C186A9DCCD Q36251948-FE9FBCCD-398A-4A84-A402-F24D6EBA96EF Q36387028-419069D4-0A2B-49D5-9B48-D4BD9B4C4F3D Q36539682-74DC4623-B8EB-4058-AA7C-B24B628AB32C Q36571197-A9FED742-A5FD-47BA-BDC9-4591B5A5292F Q36691438-2BAB831F-49D1-45CE-B3F4-AED6D4ECAAAF Q36876757-315C5241-523E-47E8-8BB9-C65E1DD2EF3E Q36999109-CBC6707D-AC2C-473E-B32A-E00AE6910411 Q37071972-A01684B0-BB35-40A5-BB87-E19E9D24782B Q37216218-07FFB6FD-6673-46AA-9C79-1070FC865D93 Q37222143-3E121C02-C737-4225-9295-1C081ACE120D Q37565475-6E420697-B9C2-4A61-810D-71BF05E23B19 Q37622486-A0B1B8EA-6AF0-43EE-AA65-CA2305D3F236 Q38195120-A747706B-362B-49F3-B341-6E8E3351DA90 Q38206719-4A79A4F1-57DD-4849-8F30-73AD9071E85F

P2860

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

http://www.wikidata.org/entity/Q37535232

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.

@en

Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.

@nl

type

label

Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.

@en

Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.

@nl

prefLabel

Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.

@en

Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.

@nl

P1433

Q37535232-D10E9B12-3444-483A-A49A-5419E74B3A05

P1476

Q37535232-0BF00DC8-3DA8-4574-BBC1-09707C3AFF1E

P2093

Q37535232-02CAFE10-472D-428D-8D57-94BDB0C58433

Q37535232-053C76DA-D904-4A2E-8A50-E64F0B68B5D4

Q37535232-24B9639A-9359-472C-B0EA-7A5DC0547FB2

Q37535232-34AF8563-F32E-445E-B813-4C3FF189444D

Q37535232-4A2A321A-8C4E-45DE-9B8B-8FB5D7AB5D0D

Q37535232-58D87EB4-5D1B-4EE1-804E-04F2A86D6F85

Q37535232-61B3AD45-E0FA-4A64-8B89-6DABA56CF18A

Q37535232-834A6BDA-E154-4C2D-898C-A8A911788693

Q37535232-88FE54E5-C44B-483E-B1A1-8D5FE8D9E24C

Q37535232-C3BEFBD6-F273-4D60-B6D3-539608DDF7E2

P2860

Q37535232-129EDF58-68A5-4DAC-9861-DC782D6009F8

Q37535232-278F970D-FE51-46C6-9746-C288E3560F41

Q37535232-34DB2BB8-CA60-4C54-8B7D-4AFAE2772877

Q37535232-3E971CA4-71BF-426E-9A86-69AB087FFEB4

Q37535232-482ED711-94B0-446B-A4A8-4EC97891B802

Q37535232-49EF47FC-ED4E-43AE-BAE4-AD1035E07585

Q37535232-51810798-483F-4B90-8B43-887A03A4841B

Q37535232-5846641A-FA91-4DD9-A452-882EFD8E5286

Q37535232-5D3AFE85-6CF3-45EF-9996-364EAD16B4C3

Q37535232-5E66D0D2-4C1D-4B72-BECC-CD0769FBE40D

P304

Q37535232-31836488-3D10-4CCF-879C-C40664F9021B

P31

Q37535232-1DFB8308-0915-4507-B535-677CA2457B8A

P356

Q37535232-42BBCF5A-7679-48C9-83D3-83BFE196CC60

P407

Q37535232-9203D2B4-F960-438C-B835-D698FF787D17

P433

Q37535232-7E119397-53AA-438E-A91E-08CD52B4D407

P478

Q37535232-A522FB77-3E05-4AB5-AADF-F7FBF2E1756A

P50

Q37535232-18C39D67-E728-4133-80FB-4CC744BBE53D

Q37535232-55343BE1-7C69-4CAD-9904-CA603A5492A9

P577

Q37535232-2EC71457-02F4-4747-A859-BD125D47ACA2

P5875

Q37535232-D51B9207-C465-4BD0-8771-CAA4BC2EDBE3

P698

Q37535232-F0816CB0-B0A6-44CD-BF58-31CE799B0B0E

P921

Q37535232-A800601F-CE8B-482F-9D1C-DE1D339CE85B

P932

Q37535232-94691732-2C5D-4D42-8B18-0F3915F5D1FF

P356

BLOOD-2013-08-519199

P1433

P1476

Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.

@en

P2093

Amanda Rajapaksa

http://www.w3.org/2001/XMLSchema#string

Ariane Thielens

http://www.w3.org/2001/XMLSchema#string

Aurelien Marabelle

http://www.w3.org/2001/XMLSchema#string

Caroline Sola

http://www.w3.org/2001/XMLSchema#string

Cécile Bonnafous

http://www.w3.org/2001/XMLSchema#string

Debra Czerwinski

http://www.w3.org/2001/XMLSchema#string

Erin Waller

http://www.w3.org/2001/XMLSchema#string

Fabien Chanuc

http://www.w3.org/2001/XMLSchema#string

François Romagné

http://www.w3.org/2001/XMLSchema#string

Holbrook E Kohrt

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The blockade of immune checkpoints in cancer immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

CD28 and CTLA-4 coreceptor expression and signal transduction

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

P304

678-686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-08-519199

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259270608

http://www.w3.org/2001/XMLSchema#string

P698

24326534

http://www.w3.org/2001/XMLSchema#string

P921

P932

3907754

http://www.w3.org/2001/XMLSchema#string